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Abstract
Ivermectin is currently approved for treatment of both clinical and veterinary infections by nematodes, including
Onchocerca cervicalis in horses and Onchocerca volvulus in humans. However, ivermectin has never been shown to be
effective against bacterial pathogens. Here we show that ivermectin also inhibits infection of epithelial cells by the bacterial
pathogen, Chlamydia trachomatis, at doses that could be envisioned clinically for sexually-transmitted or ocular infections
by Chlamydia.
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Introduction
Avermectins are macrocyclic lactone derivatives which are
produced during fermentation of Streptomyces avermectinius, a species
of actinomycete isolated from soil samples in Japan. Eight
avermectins are produced by S. avermectinius (A1a,A 1b,A 2a,A 2b,
B1a,B 1b,B 2a, and B2b). The A series molecules contain a 59-
methoxyl group, while the B series contain a 59-hydroxyl group
and have more potent anti-parasitic activity [1,2,3]. Improved
efficacy as a broad-spectrum anti-parasitic was achieved for the B1
compounds by selective hydrogenation utilizing Wilkinson’s
catalyst (RhCl(PPh3)3), with the resultant product (22,23-dihy-
droavermectin B1) being given the name ivermectin [4]. Following
considerable success as an anti-helminthic agent in veterinary
practice, including use for treatment of Onchocerca cervicalis in
horses, ivermectin entered clinical trials for use in humans against
Onchocerca volvulus, a nematode which causes onchocerciasis (‘‘river
blindness’’) [5]. Efficacious use in humans has extended to
lymphatic filariasis [6], head-lice infestation [7], and scabies [8].
However, avermectins have not been previously described to have
anti-bacterial activity [5].
Here we demonstrate that ivermectin inhibits growth of
Chlamydia trachomatis during infection of human cervical
epithelial cells, suggesting that avermectins may have previ-
ously undescribed anti-bacterial activity against pathogenic
obligate intracellular bacteria, potentially via indirect effects on
the host-cell.
Chlamydiae are obligate intracellular bacteria which mature
through a unique biphasic developmental cycle, infecting as
metabolically inert elementary bodies (EBs) and maturing into
metabolically active but non-infectious reticulate bodies (RBs),
which proliferate before condensing into infectious EBs to
complete the cycle [9,10,11]. C. trachomatis strains, which are the
leading cause of bacterial sexually transmitted disease and first
cause of preventable blindness [12], primarily infect mucosal
epithelial cells.
Results and Discussion
Five mM ivermectin added one hour post infection (hpi)
significantly inhibited the production of infectious EB
(Figure 1A) and chlamydial 16s rRNA accumulation
(Figure 1B), as evaluated by harvesting infected HeLa cultures
and infecting fresh HeLa monolayers followed by fluorescent
microscopy to determine infectious units per mL (IFU/ml,
Figure 1A), or by RNA extraction of infected HeLa cultures
f o l l o w e db yc D N As y n t h e s i sa n dq P C Rf o rC. trachomatis 16s
rRNA (Figure 1B). Treatment with 1 mMi v e r m e c t i na t1h p i
modestly decreased the size of inclusions, while inclusions in
cells treated with 5 mM ivermectin had significantly reduced
dimensions (Figure 2). Treatment with 10 mMi v e r m e c t i n
completely inhibited inclusion development. Of note, 5 mM
ivermectin did not reduce the number of cells in which
inclusions were apparent, suggesting that the effect of ivermectin
was not related to uptake of bacteria into host cells.
To exclude the possibility that ivermectin may be inhibiting
infection through an indirect cytotoxic effect on the host cells, we
verified that treatment of HeLa cells with up to 10 mM ivermectin
for 4 to 24 hours did not cause increased cell death (Figure 3A) or
lactate dehydrogenase (LDH) release (Figure 3B).
For use in humans as an anti-helminthic, ivermectin is typically
received orally at a dose of 150 mg/kg body weight, and peak
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[13]. Ivermectin has also been used and well-tolerated at 500 mg/
kg body weight via topical administration in veterinary applica-
tions [14], which could potentially be an attractive mode of use if it
is found to be effective against intracellular bacterial pathogens
which primarily infect readily accessible mucosal surfaces.
Ivermectin targets glutamate-gated chloride channels in nerve
and muscle cells and gamma-aminobutyric acid (GABA) related
chloride channels of invertebrates [5], as well as mammalian
GABA receptors [15].
Ivermectin has also been reported to interact with the
purinergic receptor, P2X4 [16], which can be stimulated by low
(micromolar) concentrations of ATP; and we have observed that
stimulation of C. trachomatis-infected epithelial cells with micromo-
lar concentrations of ATP leads to chlamydial growth inhibition
[17]. However, addition of apyrase (2.5 U/ml) to cells immedi-
ately prior to ATP addition prevents ATP-mediated chlamydial
growth inhibition (unpublished data), but does not modify the
impact of ivermectin on chlamydial growth (1 or 2.5 U/ml
apyrase, 5 mM ivermectin, N=3; data not shown). These results
suggest that ivermectin does not inhibit infection through P2X4
ligation.
We have here demonstrated that ivermectin inhibits C.
trachomatis infection in epithelial cells. While the concentrations
of ivermectin necessary for this inhibitory action in vitro are
higher than what is achieved distal to absorption sites in
current human therapy, topical application may allow thera-
peutic use of ivermectin against sexually-transmitted infection,
or against eye infection with ocular strains of C. trachomatis.
Additionally, as the target of this particular activity in human
cells has yet to be identified, other avermectins or structurally
modified avermectin molecules may have greater potency. As
it seems that ivermectin mediates this response through
interaction with a host cell target, potential efficacy against




The epithelial cell line HeLa 229 (American Type Culture
Collection, Manassas, VA) was used to model infection with the
LGV/L2 strain of C. trachomatis (obtained from Dr. Roger Rank,
University of Arkansas, Little Rock, AR). HeLa cells were cultured
in a humidified incubator at 37˚C with 5% CO2 in Dulbecco’s
modified Eagle medium (DMEM:F-12, Invitrogen) supplemented
with 10% heat-inactivated fetal calf serum. Apyrase and Hoechst
were purchased from Sigma (St. Louis, MO), and antibodies
against the C. trachomatis genus antibodies were from Argene
(Sherley, NY).
Preparation and Use of Ivermectin
A concentrated stock of ivermectin (Sigma, St. Louis, MO) was
solubilized in ethanol, and dilutions were also prepared in ethanol.
Control wells received the same concentration of ethanol (0.2%) as
treated wells, which did not influence chlamydial infection relative
to control wells without ethanol (data not shown).
Chlamydial Infection and Analysis
HeLa cells growing at 70% confluence in tissue culture plates
(Costar) were infected at a multiplicity of infection (MOI) of 1.0,
with treatments at the indicated times [18]. Infection was assayed
by fluorescence microscopy and qPCR for C. trachomatis 16s rRNA,
using protocols and primers previously described [18]. To analyze
inclusion size and morphology by fluorescent microscopy, HeLa
cells were grown on glass coverslips, and after the indicated
experimental conditions were fixed with ice cold methanol for 10
minutes. Cells were stained with C. trachomatis genus antibodies
from Argene (North Massapequa, NY) and Hoechst (Sigma), and
observed on a widefield fluorescence microscope (Leica, Deerfield,
IL).
Statistical analysis was performed using GraphPad Prism
version 5.0b for Mac (GraphPad Software, San Diego, CA).
Figure 1. Ivermectin inhibits chlamydial infection of epithelial cells. (A) HeLa cells were infected with C. trachomatis serovar L2 at an MOI of
1, followed by treatment with ivermectin at the indicated concentrations at 1 hour post infection (hpi). Samples were harvested at 24 hpi for
quantification of reinfectious yield (IFU/ml) on new HeLa cell monolayers utilizing fluorescent microscopy and anti-C. trachomatis antibodies. The
values show means plus standard deviation of three independent experiments. (n=3,**, P=0.0059). (B) Total RNA was harvested at 24 hpi for
quantification of chlamydial 16s rRNA. The values shown are relative to control values for each experiment, and are means and standard deviations of
3 independent experiments (n=3, **, P=0.0034, ***, P,0.001, compared to 100 nM condition). Two-tailed unpaired t tests were performed using
GraphPad Prism version 5.0b for Mac.
doi:10.1371/journal.pone.0048456.g001
Inhibition of Chlamydial Infection by Ivermectin
PLOS ONE | www.plosone.org 2 October 2012 | Volume 7 | Issue 10 | e48456Figure 2. Ivermectin inhibits the development of chlamydial inclusions in epithelial cells. HeLa cells grown on glass coverslips were
infected with C. trachomatis serovar L2 at an MOI of 1, followed by treatment with ivermectin at the indicated concentrations at 1 hour post infection
(hpi). At 24 hpi, cells were fixed with ice cold methanol for 10 minutes, followed by staining with C. trachomatis genus antibodies (Argene) and
Hoechst (Sigma), and observed on a widefield fluorescence microscope (Leica).
doi:10.1371/journal.pone.0048456.g002
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Figure 3. Ivermectin is not cytotoxic to epithelial cells. (A) HeLa cells were cultured in the presence of the indicated concentrations of
ivermectin or vehicle (0.2% ethanol), supernatants were then centrifuged at 500 g for 5 minutes, and adherent cells were removed with trypsin/EDTA
and gently recombined with supernatant pellets. Cell viability was determined by trypan blue exclusion, evaluated using a hemocytometer. (B)
Supernatants from the cultures described in panel A, and from wells treated with 2% Triton X-100 30 minutes prior to collection time points, were
combined and evaluated for LDH activity using a Roche Cytotoxicity Detection Kit per the manufacturer’s instructions. Shown are means plus
standard deviations for 3 independent experiments.
doi:10.1371/journal.pone.0048456.g003
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